Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7748830 | 0.76 | NFATC1 (0.58) | NFATC1GSK3BDYRK1AMAPK13MAPK12 | |
| SCHEMBL1998867 | 0.71 | KEAP1 (0.71) | SMN1; SMN2SIGMAR1KEAP1POLBCYP2D6 | |
| SCHEMBL23531450 | 0.69 | ACVR1 (0.48) | NFATC1GSK3BDYRK1ASMN1; SMN2SIGMAR1 | |
| SCHEMBL25417721 | 0.69 | KDM5A (0.43) | MAPK13MAPK12MAPK11MAPK14TLR7 | |
| SCHEMBL11222517 | 0.69 | KEAP1 (0.68) | SMN1; SMN2SIGMAR1KEAP1POLBCYP2D6 | |
| Ammonia Solution, Strong SCHEMBL9400430 | 0.69 | KEAP1 (0.68) | SMN1; SMN2SIGMAR1KEAP1POLBCYP2D6 | |
| Nimorazole SCHEMBL21836 | 0.67 | KMT2A (0.45) | SMN1; SMN2POLBCYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL7239607 | 0.66 | KEAP1 (0.71) | SMN1; SMN2SIGMAR1KEAP1POLBALDH1A1 | |
| SCHEMBL5254451 | 0.66 | ALDH1A1 (0.42) | MAPK13MAPK12MAPK11MAPK14TLR7 | |
| Nimorazole SCHEMBL2555788 | 0.66 | POLB (0.44) | SMN1; SMN2POLBCYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | NFATC1 1373/4885GSK3B 760/4885DYRK1A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.